This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Genmab (GMAB), AbbVie's Epcoritamab Successful in LBCL Study
by Zacks Equity Research
Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for hematologic malignancies including NHL and LBCL. A phase I/II study evaluating it in LBCL achieves a response rate of 63%.
Seagen (SGEN) Inks ADC Deal With Sanofi for Cancer Targets
by Zacks Equity Research
Seagen (SGEN) inks a collaboration agreement with Sanofi to develop and commercialize antibody-drug conjugates for three cancer targets.
Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag
by Zacks Equity Research
Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for non-Hodgkin's lymphoma, follicular lymphoma. The FDA grants orphan drug status for the candidate as a treatment for FL.
Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry
by Zacks Equity Research
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
Seagen (SGEN) Completes Enrollment in Colorectal Cancer Study
by Zacks Equity Research
Seagen (SGEN) enrolls the last patient in the phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin, and as a single agent for treating HER2-positive metastatic colorectal cancer.
Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer (Revised)
by Zacks Equity Research
The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer
by Zacks Equity Research
The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy
by Zacks Equity Research
AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.
Is a Surprise Coming for Genmab (GMAB) This Earnings Season?
by Zacks Equity Research
Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Seagen (SGEN) Q2 Earnings Beat Estimates, Revenues Surge Y/Y
by Zacks Equity Research
Seagen (SGEN) reports narrower-than-expected loss for the second quarter of 2021 while revenues beat estimates.
ALXN or GMAB: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALXN vs. GMAB: Which Stock Is the Better Value Option?
Seagen (SGEN) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Seagen (SGEN) lags estimates for earnings and revenues in the first quarter of 2021. Shares lose ground in after-hour trading.
Seagen's (SGEN) Tisotumab Vedotin BLA Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Seagen (SGEN) and Genmab's BLA for tisotumab vedotin under a priority review to treat recurrent/metastatic cervical cancer. A verdict is pending on Oct 10, 2021.
Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA Acceptance
by Zacks Equity Research
The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.
Seagen (SGEN) Submits BLA to FDA for Cervical Cancer Drug
by Zacks Equity Research
Seagen (SGEN) submits a BLA to the FDA for accelerated approval of tisotumab vedotin in patients with recurrent/metastatic cervical cancer, whose disease has progressed on or after chemotherapy.
J&J's (JNJ) Darzalex Faspro Gets FDA Nod for Amyloidosis
by Zacks Equity Research
J&J (JNJ) gets accelerated approval for a new indication of Darzalex Faspro in combination with bortezomib, cyclophosphamide and dexamethasone for treating amyloidosis patients.
Genmab (GMAB) Begins Phase III Study on Cervical Cancer Drug
by Zacks Equity Research
Genmab (GMAB) starts the global phase III innovaTV 301 study evaluating tisotumab vedotin versus chemotherapy for treating recurrent/metastatic cervical cancer.
AbbVie (ABBV) Outperforms Industry Year to Date: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs, Skyrizi and Rinvoq are seeing strong sales uptake.
J&J (JNJ) Files BLA for Lung Cancer Candidate Amivantamab
by Zacks Equity Research
J&J (JNJ) files a BLA to the FDA for amivantamab for the treatment metastatic non-small cell lung cancer with EGFR Exon 20 insertion mutations.
AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier
by Zacks Equity Research
AbbVie (ABBV) signs a global deal with Frontier Medicines to make innovative therapies and E3 degraders against difficult-to-drug targets.
Seattle Genetics (SGEN) to Receive Milestone Fee from Glaxo
by Zacks Equity Research
Seattle Genetics (SGEN) to win a milestone fee from GlaxoSmithKline following the EU approval of Blenrep, developed by the latter. Blenrep is made using the company's proprietary technology.
AbbVie Outperforms Large-Cap Pharma Industry Year to Date
by Zacks Equity Research
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are seeing strong sales uptake.
Genmab (GMAB) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Genmab's (GMAB) second-quarter revenues are likely to have been driven by royalties on sales of J&J's Darzalex. Several pipeline candidates are under development.
Genmab's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Genmab.
Can Genmab AS Sponsored ADR (GMAB) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Genmab AS Sponsored ADR (GMAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.